Tessari Eben 4
4 · Kiniksa Pharmaceuticals International, plc · Filed Sep 17, 2025
Insider Transaction Report
Form 4
Tessari Eben
CHIEF STRATEGY OFFICER
Transactions
- Exercise/Conversion
Share Option
2025-09-15−6,500→ 19,000 totalExercise: $8.83Exp: 2029-09-16→ Class A Ordinary Share (6,500 underlying) - Exercise/Conversion
Class A Ordinary Share
2025-09-15$8.83/sh+6,500$57,395→ 50,952 total - Sale
Class A Ordinary Share
2025-09-15$36.45/sh−16,044$584,804→ 34,908 total - Sale
Class A Ordinary Share
2025-09-15$37.00/sh−356$13,172→ 34,552 total
Footnotes (4)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $35.83 and $36.74. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.865 and $37.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F4]The option is fully vested and exercisable.